Study on Crisaborole Ointment and Laser Therapy for Non-Segmental Vitiligo
A study is underway to assess the efficacy of crisaborole ointment combined with 308-nm excimer laser for treating non-segmental vitiligo.
Phase III
Dermatology / Autoimmune Disorders
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing study on crisaborole ointment combined with excimer laser therapy could significantly enhance treatment options for non-segmental vitiligo, a challenging autoimmune disorder. Successful outcomes may shift competitive dynamics in the dermatology market, necessitating close monitoring by pharma strategy teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any subsequent publications regarding efficacy and safety outcomes.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.